Syngen Biotech Co.,Ltd. (TPEX:8279)
Taiwan
· Delayed Price · Currency is TWD 98.60
-1.40 (-1.40%)
Apr 29, 2026, 1:30 PM CST
Syngen Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2,067 | 2,136 | 2,014 | 1,837 | 1,931 | 1,471 | Upgrade
|
| Revenue Growth (YoY) | 1.74% | 6.10% | 9.60% | -4.84% | 31.22% | 12.19% | Upgrade
|
| Cost of Revenue | 1,380 | 1,413 | 1,290 | 1,193 | 1,242 | 942.93 | Upgrade
|
| Gross Profit | 687.05 | 723.59 | 723.94 | 643.92 | 688.15 | 528.34 | Upgrade
|
| Selling, General & Admin | 328.5 | 339.07 | 354.38 | 302.88 | 262.63 | 197.02 | Upgrade
|
| Research & Development | 62.15 | 60.56 | 59.34 | 46.76 | 45.32 | 49.52 | Upgrade
|
| Operating Expenses | 390.97 | 396.61 | 420.64 | 341.06 | 325.78 | 246.86 | Upgrade
|
| Operating Income | 296.08 | 326.98 | 303.3 | 302.86 | 362.38 | 281.48 | Upgrade
|
| Interest Expense | -5.05 | -5.65 | -9.28 | -8.86 | -5.07 | -3.21 | Upgrade
|
| Interest & Investment Income | 2.37 | 2.38 | 2.05 | 1.43 | 0.61 | 0.32 | Upgrade
|
| Earnings From Equity Investments | 4.43 | 8.09 | -5.32 | 36.08 | 26.64 | 14.81 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.32 | -0.32 | 5.32 | -1.93 | 10.29 | -4.31 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.78 | 3.62 | 4.18 | 4.49 | 1.58 | 7.87 | Upgrade
|
| EBT Excluding Unusual Items | 301.28 | 335.09 | 300.25 | 334.07 | 396.42 | 296.95 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.3 | 0.3 | -0.49 | 0.02 | 0.21 | 0.98 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.15 | -0.15 | -0.15 | -0.28 | -0.21 | -0.63 | Upgrade
|
| Asset Writedown | -0.4 | -0.4 | - | - | - | -1.81 | Upgrade
|
| Pretax Income | 301.03 | 334.84 | 299.61 | 333.8 | 396.42 | 295.49 | Upgrade
|
| Income Tax Expense | 57.2 | 63.25 | 59.4 | 58.98 | 75.18 | 57.72 | Upgrade
|
| Net Income | 243.83 | 271.59 | 240.21 | 274.83 | 321.24 | 237.77 | Upgrade
|
| Net Income to Common | 243.83 | 271.59 | 240.21 | 274.83 | 321.24 | 237.77 | Upgrade
|
| Net Income Growth | 0.92% | 13.07% | -12.60% | -14.45% | 35.10% | 10.31% | Upgrade
|
| Shares Outstanding (Basic) | 28 | 27 | 27 | 27 | 27 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 27 | 27 | 27 | 27 | 27 | Upgrade
|
| Shares Change (YoY) | 2.61% | 0.02% | - | -0.01% | -0.00% | -0.01% | Upgrade
|
| EPS (Basic) | 8.77 | 10.02 | 8.86 | 10.14 | 11.85 | 8.77 | Upgrade
|
| EPS (Diluted) | 8.76 | 10.01 | 8.85 | 10.13 | 11.84 | 8.76 | Upgrade
|
| EPS Growth | -1.57% | 13.11% | -12.64% | -14.44% | 35.16% | 10.33% | Upgrade
|
| Free Cash Flow | 324.34 | 255.92 | 287.83 | 323.23 | -306.79 | 274.83 | Upgrade
|
| Free Cash Flow Per Share | 11.65 | 9.43 | 10.61 | 11.91 | -11.31 | 10.13 | Upgrade
|
| Dividend Per Share | 5.000 | 5.000 | 5.000 | 5.000 | 5.000 | 4.000 | Upgrade
|
| Dividend Growth | - | - | - | - | 25.00% | 14.29% | Upgrade
|
| Gross Margin | 33.23% | 33.87% | 35.95% | 35.05% | 35.64% | 35.91% | Upgrade
|
| Operating Margin | 14.32% | 15.30% | 15.06% | 16.48% | 18.77% | 19.13% | Upgrade
|
| Profit Margin | 11.79% | 12.71% | 11.93% | 14.96% | 16.64% | 16.16% | Upgrade
|
| Free Cash Flow Margin | 15.69% | 11.98% | 14.29% | 17.59% | -15.89% | 18.68% | Upgrade
|
| EBITDA | 398.79 | 431.71 | 402.1 | 386.21 | 432.93 | 347.82 | Upgrade
|
| EBITDA Margin | 19.29% | 20.21% | 19.97% | 21.02% | 22.43% | 23.64% | Upgrade
|
| D&A For EBITDA | 102.71 | 104.73 | 98.8 | 83.35 | 70.56 | 66.34 | Upgrade
|
| EBIT | 296.08 | 326.98 | 303.3 | 302.86 | 362.38 | 281.48 | Upgrade
|
| EBIT Margin | 14.32% | 15.30% | 15.06% | 16.48% | 18.77% | 19.13% | Upgrade
|
| Effective Tax Rate | 19.00% | 18.89% | 19.83% | 17.67% | 18.96% | 19.53% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.